31 Jul 2026

CRC Research Update — July 31, 2026

Creator: The CRC Digest
Published: 2026-07-31T20:44:05Z

Today's colorectal cancer research highlights

1 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

TRIAL DATA
Dynamic ctDNA Methylation Monitoring Guides Postoperative Surveillance in FIND Trial
A prospective, randomized phase III trial tested whether circulating tumor DNA methylation monitoring can guide postoperative surveillance in nonmetastatic colorectal cancer patients. (Journal of Clinical Oncology)
TREATMENT
Liquid Biopsy Guides HER2 Therapy Rechallenge in Metastatic CRC
A study found that liquid biopsy can guide rechallenge with anti-HER2 therapy in patients with HER2-amplified metastatic colorectal cancer. (JCO Precision Oncology)
TREATMENT
First Patient Dosed in Phase 2 Trial of Oral KRAS G12D Inhibitor
Verastem Oncology has dosed the first patient in a phase 2 registration-directed trial of VS-7375, an oral KRAS G12D inhibitor, for KRAS G12D-mutated metastatic colorectal cancer. (BioSpace)
LIVING WITH CRC
Medicaid Expansion Linked to Lower Mortality in Metastatic CRC
A SEER database analysis found that Medicaid expansion was associated with decreased mortality in patients younger than 65 diagnosed with colorectal cancer and synchronous liver metastasis. (Annals of Surgery)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Unexplained Microcytosis in 40-Year-Old: Missed Opportunity for Early Diagnosis
A case report highlights how isolated microcytosis and iron deficiency in a 40-year-old male with morbid obesity was a missed early indicator of colorectal cancer. (South Dakota Medicine)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

Consensus Molecular Subtype Classification Feasible Using Preoperative Biopsies
A prospective pilot study evaluated the feasibility of consensus molecular subtype classification of colorectal cancer using preoperative biopsy specimens, examining RNA yield, quality, and concordance between different biopsy forceps. (Journal of the Anus, Rectum and Colon)

These findings highlight ongoing progress in precision medicine, early detection, and access to care for the colorectal cancer community.

Get CRC research intelligence delivered weekly — free.

Browse by Topic

KRAS Mutations Immunotherapy (MSI-H)BRAF Early-Onset / Under 50 Liver Metastases Clinical Trials Living with CRC All Issues

CRC Research Update

Subscribe to The CRC Digest